A fine line firming eye cream and a preparation method thereof

Abstract

This invention provides a wrinkle-reducing and firming eye cream and its preparation method, relating to the field of eye creams. This invention relates to an eye cream comprising the following ingredients: Phase A: water, glycerin, butylene glycol, erythritol, acrylate / C10-30 alkanol acrylate crosspolymer, p-hydroxyacetophenone, allantoin, sodium hyaluronate; Phase B1: polydimethylsiloxane, stearoxypolymethoxysiloxane / polydimethylsiloxane copolymer; Phase B2: PEG / PPG-18 / 18 polydimethylsiloxane, petrolatum, diisostearyl malate, a mixture of C20-22 phosphate ester and C20-22 alcohol, tocopheryl acetate; Phase C1: polyacrylamide, a mixture of C13-14 isoparaffin and lauryl ether-7; Phase C2: arginine, water; Phase D: gentian extract, phenoxyethanol, 1,2-hexanediol; Phase E: niacinamide, water, β-glucan, complex fermentation products, tea extract, polypeptide complex; Phase F: fragrance; The resulting eye cream exhibits significant wrinkle-reducing and firming effects, and demonstrates good safety.

Description

Technical Field

[0001] This invention relates to the field of eye creams, and in particular to a wrinkle-reducing and firming eye cream and its preparation method. Background Technology

[0002] The skin around the eyes is the thinnest and most delicate part of the human body, only one-third to one-half the thickness of the skin on other parts of the face. It lacks subcutaneous fat, collagen and elastin fibers, and the protection of sebaceous and sweat glands. It is easily affected by external environmental stimuli, bad lifestyle habits, and aging, resulting in skin problems such as dryness, fine lines, wrinkles, sagging, and drooping. Among these, fine lines, wrinkles, and sagging skin are the most concerning pain points for consumers when it comes to eye care.

[0003] With the improvement of people's living standards and the continuous enhancement of skin care awareness, anti-wrinkle and firming eye creams have become the mainstream category of eye care products, and market demand continues to grow. At present, most anti-wrinkle and firming eye creams on the market only achieve the single effect of anti-wrinkle or firming by adding a single active ingredient (such as peptides, vitamins, plant extracts, etc.). They have the defects of single effect and insufficient targeting, and cannot meet the multiple care needs of the eye skin for anti-wrinkle, firming, moisturizing and soothing at the same time.

[0004] Meanwhile, existing eye cream products still have many unreasonable aspects in their formulation design: some products add excessive amounts of thickeners or irritating ingredients in pursuit of immediate firming effects, which can easily cause discomfort such as allergies and redness around the eyes with long-term use, and even increase the metabolic burden on the skin; the formulation system of some products has poor stability, and is prone to problems such as layering, clumping, and abnormal viscosity during storage or use, which seriously affects the user experience and shelf life of the product; in addition, the ratio of active ingredients in some products lacks scientific basis, either the content of active ingredients is too low to achieve the ideal wrinkle-reducing and firming effect, or the content is too high, which not only wastes raw materials, but may also increase the risk of skin irritation.

[0005] Furthermore, in terms of manufacturing processes, existing eye creams often employ simple mixing and emulsification processes. The control over the uniformity and homogenization parameters of the oil and water phases is insufficient, resulting in coarse particles, a heavy texture, and poor absorption by the delicate skin around the eyes, thus hindering the product's ability to effectively reduce wrinkles and firm the skin. Additionally, the timing of active ingredient addition in some manufacturing processes is inappropriate, easily leading to degradation and inactivation of the active ingredients, further reducing the product's actual efficacy.

[0006] Therefore, developing a wrinkle-reducing and firming eye cream with a scientifically sound formula, mild and safe ingredients, comprehensive effects (including wrinkle reduction, firming, moisturizing, and soothing), stable formula system, simple and controllable preparation process, and full preservation of the efficacy of active ingredients has become a pressing technical challenge in the cosmetics industry. Summary of the Invention

[0007] In view of this, the present invention proposes a wrinkle-reducing and firming eye cream and its preparation method.

[0008] The technical solution of this invention is implemented as follows: A wrinkle-reducing and firming eye cream comprises the following ingredients in parts by weight: Phase A: 50-60 parts purified water, 2-6 parts glycerol, 2-5 parts butylene glycol, 1-3 parts erythritol, 0.4-0.5 parts acrylate / C10-30 alkanol acrylate crosspolymer, 0.2-0.4 parts p-hydroxyacetophenone, 0.05-0.3 parts allantoin, 0.01-0.1 parts sodium hyaluronate; Phase B1: 3-7 parts of polydimethylsiloxane alcohol, 5-10 parts of stearyloxypolymethoxysiloxane / polydimethylsiloxane copolymer; Phase B2: 0.5-2 parts PEG / PPG-18 / 18 polydimethylsiloxane, 0.3-1 part petrolatum, 0.5-1.2 parts diisostearyl malate, 0.8-1.8 parts a mixture of C20-22 phosphate ester and C20-22 alcohol, and 0.1-0.5 parts tocopheryl acetate; C1 phase: 1-2.5 parts of a mixture of polyacrylamide, C13-14 isoparaffins and lauryl alcohol polyether-7; C2 phase: 0.1-0.4 parts arginine, 1-3 parts purified water; Phase D: 0.1-0.5 parts of gentian (Gentiana scabra) extract, 0.1-0.4 parts of phenoxyethanol, and 0.1-0.5 parts of 1,2-hexanediol; Phase E: Nicotinamide 2-4 parts, purified water 1-4 parts, β-glucan 0.5-1.5 parts, complex fermentation product 3-7 parts, tea (CAMELLIASINENSIS) leaf extract 1-3 parts, polypeptide complex 0.3-0.8 parts; F phase: 0.05-0.2 parts of fragrance; The total weight of the above components is 100 parts.

[0009] Furthermore, the wrinkle-reducing and firming eye cream comprises the following ingredients in parts by weight: Phase A: 53-54 parts purified water, 3.5-4.5 parts glycerol, 2.5-3.5 parts butylene glycol, 1.5-2.5 parts erythritol, 0.4-0.5 parts acrylate / C10-30 alkanol acrylate crosspolymer, 0.25-0.35 parts p-hydroxyacetophenone, 0.1-0.2 parts allantoin, 0.02-0.04 parts sodium hyaluronate; Phase B1: 4-6 parts of polydimethylsiloxane alcohol, 7.5-8.5 parts of stearyloxypolymethoxysiloxane / polydimethylsiloxane copolymer; Phase B2: 0.8-1.2 parts of PEG / PPG-18 / 18 polydimethylsiloxane, 0.5-0.7 parts of petrolatum, 0.7-0.9 parts of diisostearyl malate, 1.0-1.5 parts of a mixture of C20-22 phosphate ester and C20-22 alcohol, and 0.2-0.4 parts of tocopheryl acetate; C1 phase: 1.5-2.0 parts of a mixture of polyacrylamide, C13-14 isoparaffins and lauryl alcohol polyether-7; C2 phase: 0.2-0.3 parts arginine, 1.5-2.5 parts purified water; Phase D: 0.2-0.4 parts of gentian (Gentiana scabra) extract, 0.2-0.3 parts of phenoxyethanol, and 0.2-0.4 parts of 1,2-hexanediol; Phase E: Nicotinamide 2.5-3.5 parts, purified water 2-4 parts, β-glucan 0.8-1.2 parts, complex fermentation product 4-6 parts, tea (CAMELLIA SINENSIS) leaf extract 1.5-2.5 parts, polypeptide complex 0.4-0.6 parts; F phase: 0.05-0.1 parts of fragrance.

[0010] Furthermore, the wrinkle-reducing and firming eye cream comprises the following ingredients in parts by weight: Phase A: 53.54 parts purified water, 4 parts glycerol, 3 parts butylene glycol, 2 parts erythritol, 0.45 parts acrylate / C10-30 alkanol acrylate crosspolymer, 0.3 parts p-hydroxyacetophenone, 0.15 parts allantoin, and 0.03 parts sodium hyaluronate; Phase B1: 5 parts of polydimethylsiloxane alcohol and 8 parts of stearyloxypolymethoxysiloxane / polydimethylsiloxane copolymer; Phase B2: 1 part PEG / PPG-18 / 18 polydimethylsiloxane, 0.6 parts petrolatum, 0.8 parts diisostearyl malate, 1.3 parts a mixture of C20-22 phosphate ester and C20-22 alcohol, and 0.3 parts tocopheryl acetate; C1 phase: 1.8 parts of a mixture of polyacrylamide, C13-14 isoparaffins and lauryl alcohol polyether-7; C2 phase: 0.28 parts arginine, 2 parts purified water; Phase D: 0.3 parts Gentiana scabra extract, 0.25 parts phenoxyethanol, and 0.3 parts 1,2-hexanediol; Phase E: 3 parts nicotinamide, 3 parts purified water, 1 part β-glucan, 5 parts compound fermentation product, 2 parts tea (CAMELLIASINENSIS) leaf extract, 0.5 parts polypeptide complex; Phase F: 0.1 parts of fragrance.

[0011] Furthermore, the mass ratio of C20-22 alcohol phosphate to C20-22 alcohol in the C20-22 alcohol mixture is 1-3:1.

[0012] Furthermore, the mass ratio of polyacrylamide, C13-14 isoparaffin, and lauryl ether-7 in the mixture is 4-6:3-5:1.

[0013] Furthermore, the polypeptide complex is composed of acetyl hexapeptide-8, palmitoyl pentapeptide-4, palmitoyl tripeptide-1, and acetyl tetrapeptide-5, and the mass ratio of acetyl hexapeptide-8, palmitoyl pentapeptide-4, palmitoyl tripeptide-1, and acetyl tetrapeptide-5 in the polypeptide complex is (8-12):(4-6):(1-3):(0.8-1.2).

[0014] Furthermore, the composite fermentation product is composed of Bifida ferment lysate and Lactobacillus fermentation product, and the mass ratio of Bifida ferment lysate to Lactobacillus fermentation product in the composite fermentation product is 3-5:1.

[0015] The preparation method of the wrinkle-reducing and firming eye cream of the present invention includes the following steps: (1) Add phase A raw material to the emulsification pot, stir and heat to 75-85℃, homogenize and disperse for 2-5 minutes, and continue stirring until the material is completely dissolved; (2) Add the B2 phase raw material to the oil phase pot and heat it to 75-85℃. Stir until completely dissolved, then add the B1 phase raw material and stir evenly to obtain the B phase. (3) Pour phase B into the emulsifying pot and stir to homogenize for 3-8 minutes; (4) Cool down to 55-65℃, add C1 phase raw material into the emulsifying pot, and homogenize for 3-8 minutes; (5) Add the C2 phase raw material into the emulsifying pot, stir evenly, vacuum, and keep warm for 15-25 minutes; (6) Cool down to 40-50℃, add D phase, E phase and F phase raw materials into the emulsification pot in sequence, homogenize for 3-8 minutes, vacuum, and stir for 5-15 minutes; (8) Cool down to 35-40℃, stop stirring and cool down, filter and discharge the material to obtain the wrinkle-reducing and firming eye cream.

[0016] Furthermore, the method for preparing the wrinkle-reducing and firming eye cream of the present invention includes the following steps: (1) Add phase A raw material to the emulsification pot, stir and heat to 80°C, homogenize and disperse for 3 minutes, and continue stirring until the material is completely dissolved; (2) Add the B2 phase raw material to the oil phase pot and heat it to 80°C. Stir until completely dissolved, then add the B1 phase raw material and stir evenly to obtain the B phase. (3) Pour phase B into the emulsifying pot and stir to homogenize for 5 minutes; (4) Cool down to 60°C, add the C1 phase raw material into the emulsifying pot, and homogenize for 5 minutes; (5) The C2 phase raw material is added into the emulsifying pot and stirred evenly, then vacuumed and kept warm for 20 minutes; (6) Cool down to 45°C, add D phase, E phase and F phase raw materials into the emulsification pot in sequence, homogenize for 5 minutes, vacuum, and stir for 10 minutes; (8) Cool down to 38°C, stop stirring and cool down, filter and discharge the material to obtain the wrinkle-reducing and firming eye cream.

[0017] Furthermore, the homogenization speed in the emulsifying pot is 2400-2700 rpm.

[0018] Furthermore, the stirring speed in the oil phase pot is 15-25 rpm.

[0019] Furthermore, the pretreatment before step (1) includes: mixing and dispersing butanediol and sodium hyaluronate in phase A evenly; mixing and dispersing polydimethylsiloxane alcohol and stearoxypolymethoxysiloxane / polydimethylsiloxane copolymer in phase B1 evenly; dissolving arginine in phase C2 evenly with purified water before use; and dissolving nicotinamide in phase E evenly with purified water before use.

[0020] Compared with the prior art, the beneficial effects of the present invention are: This invention's eye cream exhibits significant anti-wrinkle and wrinkle-reducing effects, promoting the proliferation of human skin fibroblasts, delaying skin cell aging, and improving fine lines and wrinkles. It also boasts outstanding firming effects, significantly improving skin elasticity. The synergistic effect of the active ingredients in the formula achieves a dual anti-aging effect of reducing wrinkles and firming the skin. Furthermore, it is highly safe, causing no skin or eye irritation and exhibiting no significant toxicity, making it safe for use on the delicate skin around the eyes and suitable for a wide range of people. This invention's eye cream combines high safety with excellent anti-aging efficacy. Its scientifically formulated recipe meets anti-aging skincare needs, demonstrating promising application value and market prospects.

[0021] (1) Comprehensive efficacy and strong synergy, with significant wrinkle reduction and firming effect: This invention uses a reasonable ratio of polypeptide complex, combined with active ingredients such as compound fermentation products, gentian extract, tea leaf extract and niacinamide. The synergistic effect of each ingredient can effectively inhibit the release of neurotransmitters, promote collagen synthesis, reduce the formation of fine lines and dry lines around the eyes and lighten existing lines, improve the elasticity of the skin around the eyes, improve skin laxity and sagging, and achieve the effects of moisturizing, locking in purified water, soothing and anti-inflammatory. It fully meets the multiple care needs of the skin around the eyes and solves the technical problem of single efficacy of existing products.

[0022] (2) The formula is mild and safe with low irritation: This invention avoids excessive addition of thickeners or irritating substances by precisely controlling the weight range of each component, especially the amount of irritating ingredients. This reduces the risk of eye skin allergies and redness, is suitable for delicate eye skin, and will not increase the metabolic burden on the skin with long-term use, making it safer.

[0023] (3) Stable formulation system and long shelf life: This invention optimizes the ratio of each component in phases A, B, C, D, E and F, especially the ratio of oil phase component to purified water phase component, and combines precise preparation process to make the eye cream system uniform and stable. Under normal storage and use conditions, it is not easy to have problems such as clumping or abnormal viscosity, effectively extending the product shelf life and improving the user experience.

[0024] (4) The preparation process is simple and controllable, and the retention rate of active ingredients is high: The present invention optimizes the preparation parameters of oil phase and purified water phase, as well as homogenization and stirring speed, and accurately controls the temperature and time of each step, which can effectively avoid the degradation and inactivation of active ingredients due to high temperature, and fully retain the efficacy of each active ingredient; at the same time, the process parameters are suitable for laboratory small-scale tests and industrial large-scale production, the operation is simple and controllable, no complex equipment is required, the production cost is reduced, and it is easy to promote and apply on a large scale.

[0025] (5) Excellent skin feel and good absorption: This invention uses a reasonable combination of siloxane raw materials, skin esters and moisturizing components, combined with a precise homogenization process, to make the eye cream delicate, refreshing and non-greasy, easy to be absorbed by the delicate skin around the eyes, and able to quickly penetrate into the deep layers of the skin to exert its effects, avoiding the waste of efficacy caused by a heavy skin feel and poor absorption, and further improving the product's user experience and care effect. Detailed Implementation

[0026] Unless otherwise specified, the experimental methods used in the embodiments of this invention are conventional methods; Unless otherwise specified, all materials and reagents used in the embodiments of this invention are commercially available.

[0027] In this embodiment of the invention, Acrylates / C10-30 alkanolate crosspolymers, stearoxymethicone / dimethicone copolymers, PEG / PPG-18 / 18 dimethicone, Bifida ferment lysate, and Lactobacillus ferment are all commercially available cosmetic ingredients. In phase B2, the mass ratio of C20-22 alcohol phosphate to C20-22 alcohol is 2:1. The mass ratio of polyacrylamide, C13-14 isoparaffins and lauryl alcohol polyether-7 in the C1 phase is 5:4:1. The mass ratio of Bifida ferment lysate to Lactobacillus ferment lysate in phase E is 4:1. In phase E, the mass ratio of acetyl hexapeptide-8, palmitoyl pentapeptide-4, palmitoyl tripeptide-1, and acetyl tetrapeptide-5 is 10:5:2:1.

[0028] Example 1 1. Formula Table 1 Formulation of Example 1

[0029] 2. Process Pretreatment: Mix and disperse raw materials (3, 8) evenly; mix and disperse raw materials (9, 10) evenly; dissolve raw materials (17, 18) evenly; dissolve raw materials (22, 23) evenly.

[0030] (1) Add phase A (raw materials 1-8) to the emulsification pot, stir and heat to 80°C, then homogenize and disperse for 3 minutes, and continue stirring until the material is completely dissolved.

[0031] (2) Add phase B2 (raw materials 11-15) to the oil phase pot and heat to 80°C, stirring until completely dissolved. Add phase B1 (raw materials 9-10) to the oil phase pot and stir evenly.

[0032] (3) Pour phase B into the emulsifying pot and stir to homogenize for 5 minutes.

[0033] (4) Cool down to 60°C, put the C1 phase (raw material 16) into the emulsifying pot, and homogenize for 5 minutes.

[0034] (5) Add the C2 phase (raw material 17-18) into the emulsifying pot and stir evenly. Vacuum and keep warm for 20 minutes.

[0035] (6) Reduce the temperature to 45°C, and add phase D (raw material 19-21), phase E (raw material 22-27), and phase F (raw material 28) into the emulsification pot in sequence. Homogenize for 5 minutes, vacuum, and stir for 10 minutes.

[0036] (7) Cool down to 38°C, stop stirring and cool down. After passing the inspection, filter the material with a 100-mesh sterilized filter cloth.

[0037] Example 2 1. Formula Table 2 Formulation of Example 2

[0038] 2. Process Consistent with Example 1.

[0039] Example 3 1. Formula Table 3 Formulation of Example 3

[0040] 2. Process Consistent with Example 1.

[0041] Example 4 1. Formula Table 4 Formulation of Example 4

[0042] 2. Process Consistent with Example 1.

[0043] Example 5 1. Formula Table 5 Formulation of Example 5

[0044] 2. Process Consistent with Example 1.

[0045] Comparative Example 1 The main difference from Example 1 is that the gentian extract in phase D is replaced with tea leaf extract (0.30%wt, i.e., the amount added is unchanged), and the tea leaf extract in phase E is replaced with gentian extract (2.0%wt, i.e., the amount added is unchanged).

[0046] Comparative Example 2 The main difference from Example 1 is that the polypeptide complex in phase E is composed of acetyl hexapeptide-8, palmitoyl pentapeptide-4, palmitoyl tripeptide-1, and acetyl tetrapeptide-5 in a mass ratio of 1:1:1:1.

[0047] Comparative Example 3 The main difference from Example 1 is that the mass ratio of Bifida ferment lysate and Lactobacillus ferment lysate in the E phase of the composite fermentation product is 1:4.

[0048] Test Example 1 - Safety Test In accordance with the requirements of the "Cosmetic Safety Technical Specifications (2015 Edition)," the eye cream sample from Example 1 was selected for acute skin toxicity tests, skin irritation tests, and eye irritation tests. SPF-grade Balb / c mice, aged 8–10 weeks and weighing 18–22 g, were used as test animals. The animals were sourced from the Guangdong Provincial Medical Laboratory Animal Center. Each group consisted of 10 mice, half male and half female. The tests began after a 3-day acclimatization period. All animals were housed in a standard environment with a temperature of 20–25℃, humidity of 40%–60%, and a 12-hour light-dark cycle, provided with standard feed and clean drinking water, and had free access to food and water.

[0049] (1) Acute skin toxicity test: After continuous observation for 7 days, no mice died. The fur of the test animals was shiny and their growth was good. No abnormal symptoms such as redness, swelling or damage were observed on the skin at the application site. The eye cream of this invention has no obvious skin toxicity.

[0050] (2) Skin irritation test: No irritating pathological manifestations such as erythema and edema appeared in the area of ​​the test animal sample. It was determined that the skin irritation level of the eye cream of the present invention is non-irritating.

[0051] (3) Eye irritation test: The eye cream of the present invention was applied to the eyes of the test animals daily, one drop at a time, twice a day, for 15 days. The condition of the eye tissue was observed throughout the process. During the test period, no abnormal phenomena such as congestion, inflammation, or damage were observed in the periorbital and intraocular tissues of the mice. The results showed that the eye cream of the present invention did not cause any irritation or damage to the eye tissues.

[0052] Experimental Example 2 - Assay for Promoting Human Skin Fibroblast Proliferation (MTT Method) The eye creams prepared in Examples 1-5 and Comparative Examples 1-3 were used to prepare a liquid with an effective content of 10% as the test sample.

[0053] Human skin fibroblasts in the logarithmic growth phase were selected, digested, and cultured in DMEM medium containing 15% fetal bovine serum and 1% penicillin-dextrose antibody to prepare a cell concentration of 1×10⁶ cells / cells. 5Cell suspension was prepared at / mL; 150μL of the cell suspension was seeded into each well of a 96-well plate and cultured at 37℃ and 5% for 24h. The original culture medium was discarded and replaced with DMEM medium supplemented with 50μg / mL of the test sample, 15% fetal bovine serum, and 1% penicillin antibiotics, and cultured for another 24h. The culture medium was aspirated, and after washing with PBS, 150μL of the above DMEM medium and 20μL of 5mg / mL MTT solution were added to each well, and incubated at 37℃ and 5% for 4h. The supernatant was discarded, and 150μL of LDMSO was added to each well, and the mixture was shaken for 10min until the crystals were completely dissolved. A blank control group was set up simultaneously, with physiological saline replacing the test sample; all other experimental conditions were the same, and each group had 5 replicates. The absorbance of each well was measured at 490nm using a microplate reader. Each experiment was performed in parallel five times, and the average value was taken. The cell proliferation rate was calculated using the following formula: Proliferation rate (%) = (Absorbance of sample tested - Absorbance of control group) ÷ Absorbance of control group × 100% The results of each group of experiments are shown in Table 6.

[0054] Table 6 Anti-wrinkle effects of eye cream

[0055] The eye cream of this invention can significantly promote the proliferation of human skin fibroblasts and effectively delay skin cell aging. The eye cream of this invention also has a good anti-wrinkle effect.

[0056] Experimental Example 3 One hundred and sixty healthy female subjects aged 30-50 with dry lines, fine lines and reduced skin elasticity around the eyes were selected and randomly divided into eight groups, including experimental groups 1-8, with 20 people in each group. There was no significant difference in the average age among the groups.

[0057] Experimental Methods: After cleansing their skin with warm water, volunteers in each group used a skin elasticity tester to measure the skin elasticity parameter R1 around their eyes. The measurement was repeated 3 times and the average value was taken. Subsequently, 3 mL of the corresponding test sample (eye cream of Examples 1-5 and Comparative Examples 1-3) was evenly applied to the skin around the eyes of the subjects and gently massaged with the fingertips until fully absorbed. The samples were used once in the morning and once in the evening for 8 consecutive weeks. During the experiment, other similar products were prohibited from use, and the same test sample was used by the subjects in the same group.

[0058] After the 8-week trial, the same skin elasticity testing instrument was used to measure the skin elasticity parameter R2 again on the same periorbital area of ​​the subjects. The measurement was repeated 3 times and the average value was taken. R1 and R2 both represent the ratio of the skin rebound without negative pressure to the maximum stretch of the skin with negative pressure, reflecting the degree of skin recovery within one cycle after negative pressure deformation. The closer the value is to 1, the better the skin elasticity.

[0059] The formula for calculating the skin elasticity improvement rate is: Skin elasticity improvement rate = (R2-R1) / R1×100%.

[0060] The results are shown in Table 7.

[0061] Table 7. Improvement rate of eye cream on elasticity of skin around the eyes

[0062] As shown in Table 2, the eye cream of this invention can significantly improve skin elasticity. The active ingredients in the eye cream formula of this invention work synergistically to effectively maintain and enhance skin elasticity, achieving excellent anti-aging and skincare effects.

[0063] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the scope of protection of the present invention.

Claims

1. A wrinkle-reducing and firming eye cream, characterized in that, Including the following parts by weight of raw materials: Phase A: 50-60 parts water, 2-6 parts glycerol, 2-5 parts butylene glycol, 1-3 parts erythritol, 0.4-0.5 parts acrylate / C10-30 alkanol acrylate crosspolymer, 0.2-0.4 parts p-hydroxyacetophenone, 0.05-0.3 parts allantoin, 0.01-0.1 parts sodium hyaluronate. Phase B1: 3-7 parts of polydimethylsiloxane alcohol, 5-10 parts of stearoxy polymethoxysiloxane / polydimethylsiloxane copolymer Phase B2: 0.5-2 parts PEG / PPG-18 / 18 polydimethylsiloxane, 0.3-1 part petrolatum, 0.5-1.2 parts diisostearyl malate, 0.8-1.8 parts a mixture of C20-22 phosphate ester and C20-22 alcohol, and 0.1-0.5 parts tocopheryl acetate. C1 phase: 1-2.5 parts of a mixture of polyacrylamide, C13-14 isoparaffins and lauryl alcohol polyether-7. C2 phase: 0.1-0.4 parts arginine, 1-3 parts water. Phase D: 0.1-0.5 parts of gentian (Gentiana scabra) extract, 0.1-0.4 parts of phenoxyethanol, and 0.1-0.5 parts of 1,2-hexanediol. Phase E: Nicotinamide 2-4 parts, water 1-4 parts, β-glucan 0.5-1.5 parts, complex fermentation product 3-7 parts, tea (Camellia sinensis) leaf extract 1-3 parts, polypeptide complex 0.3-0.8 parts. F phase: 0.05-0.2 parts of fragrance.

2. The wrinkle-reducing and firming eye cream according to claim 1, characterized in that, Including the following parts by weight of raw materials: Phase A: Water 53-54 parts, Glycerin 3.5-4.5 parts, Butylene Glycol 2.5-3.5 parts, Erythritol 1.5-2.5 parts, Acrylic (ester) / C10-30 Alkyl Acrylate Crosspolymer 0.4-0.5 parts, p-Hydroxyacetophenone 0.25-0.35 parts, Allantoin 0.1-0.2 parts, Sodium Hyaluronate 0.02-0.04 parts. Phase B1: 4-6 parts of polydimethylsiloxane alcohol, 7.5-8.5 parts of stearoxypolymethoxysiloxane / polydimethylsiloxane copolymer. Phase B2: 0.8-1.2 parts of PEG / PPG-18 / 18 polydimethylsiloxane, 0.5-0.7 parts of petrolatum, 0.7-0.9 parts of diisostearyl malate, 1.0-1.5 parts of a mixture of C20-22 phosphate ester and C20-22 alcohol, and 0.2-0.4 parts of tocopheryl acetate; C1 phase: 1.5-2.0 parts of a mixture of polyacrylamide, C13-14 isoparaffins, and lauryl alcohol polyether-7. C2 phase: 0.2-0.3 parts arginine, 1.5-2.5 parts water. Phase D: Gentian (Gentiana scabra) extract 0.2-0.4 parts, phenoxyethanol 0.2-0.3 parts, 1,2-hexanediol 0.2-0.4 parts. Phase E: Nicotinamide 2.5-3.5 parts, water 2-4 parts, β-glucan 0.8-1.2 parts, complex fermentation product 4-6 parts, tea (Camellia sinensis) leaf extract 1.5-2.5 parts, polypeptide complex 0.4-0.6 parts. F phase: 0.05-0.1 parts of fragrance.

3. The wrinkle-reducing and firming eye cream according to claim 1, characterized in that, Including the following parts by weight of raw materials: Phase A: Water 53.54 parts, Glycerin 4 parts, Butylene Glycol 3 parts, Erythritol 2 parts, Acrylic (Ester) / C10-30 Alkyl Acrylate Crosspolymer 0.45 parts, p-Hydroxyacetophenone 0.3 parts, Allantoin 0.15 parts, Sodium Hyaluronate 0.03 parts. Phase B1: 5 parts polydimethylsiloxane alcohol, 8 parts stearoxy polymethoxysiloxane / polydimethylsiloxane copolymer Phase B2: 1 part PEG / PPG-18 / 18 polydimethylsiloxane, 0.6 parts petrolatum, 0.8 parts diisostearyl malate, 1.3 parts a mixture of C20-22 phosphate ester and C20-22 alcohol, and 0.3 parts tocopheryl acetate. C1 phase: 1.8 parts of a mixture of polyacrylamide, C13-14 isoparaffins and lauryl alcohol polyether-7. C2 phase: 0.28 parts arginine, 2 parts water, Phase D: 0.3 parts Gentiana scabra extract, 0.25 parts phenoxyethanol, 0.3 parts 1,2-hexanediol. Phase E: Nicotinamide 3 parts, Water 3 parts, β-glucan 1 part, Complex fermentation product 5 parts, Tea (Camellia sinensis) leaf extract 2 parts, Peptide complex 0.5 parts. Phase F: 0.1 parts of fragrance.

4. The wrinkle-reducing and firming eye cream according to claim 1, characterized in that, The mass ratio of C20-22 alcohol phosphate to C20-22 alcohol in the mixture of C20-22 alcohol and C20-22 alcohol is 1-3:

1.

5. The wrinkle-reducing and firming eye cream according to claim 1, characterized in that, The mass ratio of polyacrylamide, C13-14 isoparaffin, and lauryl ether-7 in the mixture is 4-6:3-5:

1.

6. The wrinkle-reducing and firming eye cream according to claim 1, characterized in that, The polypeptide complex is composed of acetyl hexapeptide-8, palmitoyl pentapeptide-4, palmitoyl tripeptide-1, and acetyl tetrapeptide-5, and the mass ratio of acetyl hexapeptide-8, palmitoyl pentapeptide-4, palmitoyl tripeptide-1, and acetyl tetrapeptide-5 in the polypeptide complex is (8-12):(4-6):(1-3):(0.8-1.2).

7. The wrinkle-reducing and firming eye cream according to claim 1, characterized in that, The compound fermentation product is composed of Bifida ferment lysate and Lactobacillus fermentation product, and the mass ratio of Bifida ferment lysate to Lactobacillus fermentation product in the compound fermentation product is 3-5:

1.

8. A method for preparing the wrinkle-reducing and firming eye cream according to any one of claims 1-7, characterized in that, Includes the following steps: (1) Add phase A raw material to the emulsification pot, stir and heat to 75-85℃, homogenize and disperse for 2-5 minutes, and continue stirring until the material is completely dissolved; (2) Add the B2 phase raw material to the oil phase pot and heat it to 75-85℃. Stir until completely dissolved, then add the B1 phase raw material and stir evenly to obtain the B phase. (3) Pour phase B into the emulsifying pot and stir to homogenize for 3-8 minutes; (4) Cool down to 55-65℃, add C1 phase raw material into the emulsifying pot, and homogenize for 3-8 minutes; (5) Add the C2 phase raw material into the emulsifying pot, stir evenly, vacuum, and keep warm for 15-25 minutes; (6) Cool down to 40-50℃, add D phase, E phase and F phase raw materials into the emulsification pot in sequence, homogenize for 3-8 minutes, vacuum, and stir for 5-15 minutes; (8) Cool down to 35-40℃, stop stirring and cool down, filter and discharge the material to obtain the wrinkle-reducing and firming eye cream.

9. The method for preparing the wrinkle-reducing and firming eye cream according to claim 7, characterized in that, The homogenization speed in the emulsification pot is 2400-2700 rpm; the stirring speed in the oil phase pot is 15-25 rpm.

10. The method for preparing the wrinkle-reducing and firming eye cream according to claim 7, characterized in that, The pretreatment in step (1) includes: mixing and dispersing butanediol and sodium hyaluronate in phase A evenly; mixing and dispersing polydimethylsiloxane alcohol and stearoxypolymethoxysiloxane / polydimethylsiloxane copolymer in phase B1 evenly; dissolving arginine in phase C2 evenly with water before use; and dissolving nicotinamide in phase E evenly with water before use.

Images